TAK-573-2001: Modakafusp alfa in Combination with Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Sponsor: Takeda Development Center Americas, Inc
Full Title
TAK-573-2001: A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma
Study Treatment
Anti-CD38-targeted IgG4-attenuated IFNa Modakafusp alfa in combination with daratumumab
Eligibility/Info
Relapsed/refractory multiple myeloma.
Treatment history must be one of:
- Three prior lines of treatment including at least 1 proteasome inhibitor (PI), 1 immunomodulatory drug (IMiD), and 1 anti-CD38 antibody.
- Triple refractory to a PI, IMiD, and anti-CD38 antibody regardless of the number of lines of therapy.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
